冠状动脉钙化（CAC）增加急性冠状动脉综合征的风险。这项研究检查了C1q/TNF相关蛋白9（CTRP9）与CAC之间的相关性，并探讨了CTRP9作为预后生物标志物的作用。我们将275例冠心病患者分为四组。为了平衡基线混杂因素，进行倾向评分匹配(PSM),使CAC患者与非CAC患者以1:1的比例进行匹配.对126例CAC患者进行光学相干断层扫描(OCT)钙化评分。此外，140例接受OCT检查的患者随访9个月，分析CTRP9水平与临床预后的相关性。根据OCT钙化评分,将126例CAC患者分为0-2组和3-4组。2型糖尿病（T2DM）患者血浆CTRP9水平显著降低，CAC和CAC伴T2DM组优于对照组。CTRP9是CAC严重程度的保护因子和潜在预测因子。根据血浆CTRP9水平预测的OCT钙化评分3-4组的AUC为0.766。在后续期间,低水平CTRP9(L-CTRP9)组的累积无事件生存率显著低于高水平(H-CTRP9)组,L-CTRP9组的主要终点事件发生率明显高于H-CTRP9组。CTRP9可以作为CAC发生和严重程度的有价值的生物标志物，并可以预测患者的临床预后。
Coronary artery calcification (CAC) increases the risk of acute coronary syndrome. This
study examined the correlation between C1q/TNF-related protein 9 (
CTRP9) and CAC and explored
CTRP9 as a biomarker for prognosis. We divided 275 patients with coronary heart disease into four groups. In order to balance the baseline confounding factors, propensity score matching (PSM) was performed to match CAC patients with non-CAC patients in a 1:1 ratio. Optical coherence tomography (OCT) calcification scoring was performed in 126 patients with CAC. Moreover, 140 patients who underwent OCT were followed-up for 9 months for analysis of the correlation between CTRP9 levels and clinical prognosis. Based on OCT calcification scores, 126 patients with CAC were divided into the 0-2 and 3-4 groups. Plasma CTRP9 levels were significantly lower in the type 2 diabetes mellitus (T2DM), CAC and CAC with T2DM groups than in the control group.
CTRP9 played roles as a protective factor and potential predictor in CAC severity. The AUC of the OCT calcification score 3-4 group predicted by the plasma
CTRP9 level was 0.766. During the follow-up period, the cumulative event-free survival rate was significantly lower in the low-level CTRP9 (L-
CTRP9) group than in the high-level (H-
CTRP9) group, and the incidence of major endpoint events was significantly higher in the L-
CTRP9 group than in the H-
CTRP9 group. CTRP9 can be a valuable biomarker for CAC occurrence and severity and can predict patients\' clinical prognosis.
